Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 435.10A |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Testosterone supplemented |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
4 |
| Average PDX Generation Time (days +/- SEM) | 57 ± 4 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 435.10A |
|---|---|
| AR | N |
| PSA | N |
| PSMA | N |
| NE | Y |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 435.10A | PIK3CB | 1.269 | 4.821 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | IGF2R | 0.559 | 2.947 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | MYC | 1.001 | 4.003 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | NCOR2 | 0.574 | 2.978 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | PRPF8 | 0.530 | 2.888 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | SETDB1 | 0.585 | 2.999 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | TP53 | -28.452 | 5.450e-09 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | CUL3 | -0.940 | 1.042 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | CHD1 | -0.958 | 1.029 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | APC | -0.958 | 1.029 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | SUFU | -0.954 | 1.032 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | PAX6 | -0.953 | 1.033 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | USP28 | -0.966 | 1.024 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | CDKN1B | -0.931 | 1.049 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | BRCA2 | -0.995 | 1.004 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | RB1 | -1.410 | 0.753 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | MGA | -0.969 | 1.022 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | AXIN1 | -0.880 | 1.087 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | CDH1 | -0.976 | 1.016 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | ZFHX3 | -0.976 | 1.016 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | FANCA | -0.976 | 1.016 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | ZNRF3 | -0.963 | 1.026 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.10A | ERBB4 | -0.940 | 1.042 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 435.10A |
|---|---|
| Sample Site | Left lateral cerebellum |
| Sample source | Autopsy |
| Pathology Tumour Diagnosis | None |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | ADT, carboplatin plus etoposide |
Patient Information
| Patient Number | 435 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | 16.2 |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 435.10A |
| Patient Age (binned in 5 year age groups) | 65-72 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 435.10A | BRCA2 | 176 | 0.99 | Frameshift variant | '11/28 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.10A | SUPV3L1 | 495 | 0.67 | Missense variant | '13/15 | . | 31 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.10A | PRKDC | 265 | 0.55 | Missense variant | '1/87 | . | 24.9 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.10A | IRF4 | 394 | 0.51 | Missense variant | '3/9 | 3.66E-05 | 21.5 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.10A | ATAD2B | 273 | 0.5 | Missense variant | '1/28 | . | 25.1 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.10A | TSHR | 413 | 0.49 | Missense variant | '11/11 | . | 27.2 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.10A | NTRK2 | 330 | 0.48 | Missense variant | '10/21 | . | 27.3 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.10A | NOTCH2 | 434 | 0.42 | Frameshift variant | '34/34 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Drug dosing Table